| Chaudri G Rasool, DO | |
|
110 Jefferson St, West Union, IA 52175-1022 | |
| (563) 422-3817 | |
| Not Available |
| Full Name | Chaudri G Rasool |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 110 Jefferson St, West Union, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285636456 | NPI | - | NPPES |
| 32373300 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 3033 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Chaudri G Rasool, DO 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 | Chaudri G Rasool, DO 110 Jefferson St, West Union, IA 52175-1022 Ph: (563) 422-3817 |
News Archive
A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib-the only approved ALK inhibitor. Results of this Novartis-sponsored sudy will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
Scientists still do not know what causes epileptic seizures, but researchers from Melbourne's Howard Florey Institute are one step closer to solving this puzzle with the help of their newly developed genetically modified epileptic mouse.
Optimer Pharmaceuticals, Inc. announced the presentation of new data from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection. The data, presented by Stuart Johnson, M.D. during an oral session at the annual meeting of Digestive Disease Week in New Orleans, indicated that treatment with fidaxomicin significantly improved the recurrence rate and global cure rate in CDI patients requiring concomitant antibiotics, compared to vancomycin.
Researchers from Peter the Great St.Petersburg Polytechnic University (SPbPU) in collaboration with colleagues from Belgium take a step in the development of genome editing technology.
› Verified 6 days ago
Geralyn R Zuercher, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 Jefferson St, West Union, IA 52175 Phone: 563-422-3817 | |
Kenneth A Miller, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 110 Jefferson St, West Union, IA 52175 Phone: 563-422-3817 | |
Carina Crookston, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 Jefferson St, West Union, IA 52175 Phone: 563-422-3817 | |
Stephen Paul Daniel, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 112 Jefferson St, West Union, IA 52175 Phone: 563-422-3811 |